Mayzent · Neuroscience · revenue 1068 Mayzent works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression.
Scemblix · Oncology · revenue 894 Scemblix works by blocking the ABL1 enzyme, which is involved in the growth and survival of cancer cells.
Leqvio · Metabolic · revenue 863 Leqvio works by binding to PCSK9, preventing it from breaking down LDL receptors.
Afinitor · Oncology · revenue 600 Afinitor works by blocking the mTOR protein, which is involved in cell growth and division.
Promacta · Oncology · revenue 569 Promacta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow.
Diovan · Metabolic · revenue 447 Diovan works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure.
Pluvicto · Oncology · revenue 386 Pluvicto works by binding to prostate-specific antigen (PSMA) on cancer cells, delivering a radioactive payload that kills the cells.
Pluvicto · Oncology · revenue 386 Pluvicto works by binding to the PSMA protein on prostate cancer cells, delivering a radioactive payload to destroy the cancer cells.
Sandostatin · Oncology · revenue 305 Sandostatin works by mimicking the natural hormone somatostatin to inhibit the release of various hormones and growth factors.
Tabrecta · Oncology · revenue 200 Tabrecta works by blocking the hepatocyte growth factor receptor, a protein that helps cancer cells grow and spread.
Rydapt · Oncology · revenue 200 Rydapt blocks the activity of the Kit receptor, which is involved in the growth and survival of cancer cells.
Agriflu (TIV) · Immunology / Infectious Disease Agriflu is a trivalent inactivated influenza vaccine that stimulates the immune system to produce antibodies against three strains of influenza virus.
Aliskiren Hydrochlorothiazide · Cardiovascular Aliskiren hydrochlorothiazide combines a direct renin inhibitor with a thiazide diuretic to lower blood pressure through dual mechanisms of renin-angiotensin system suppression and sodium/fluid reduction.
Piqray · Oncology Alpelisib inhibits PI3Kα, blocking Akt-signaling and preventing tumor growth and organ abnormalities in PROS disorders.
Scemblix · Oncology Asciminib binds to the ABL myristoyl pocket, inhibiting ABL1 kinase activity of BCR::ABL1, including mutant forms.
Aspirin, acetaminophen and caffeine · Pain Management This combination analgesic and antipyretic works through multiple pathways: aspirin inhibits cyclooxygenase to reduce prostaglandins, acetaminophen inhibits pain and fever centers in the CNS, and caffeine enhances analgesic efficacy while promoting alertness.
Vanrafia · Immunology Vanrafia works by binding to and blocking the activity of a specific receptor involved in the progression of IgAN.
Betoptic · Cardiovascular Betaxolol works by blocking the beta-1 adrenergic receptor in the heart and eyes, reducing heart rate and pressure, and decreasing intraocular pressure.
Angiomax · Cardiovascular Bivalirudin directly inhibits thrombin by binding to its catalytic site and anion-binding exosite, preventing thrombus formation.
Branded Tacrolimus · Immunology Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, preventing IL-2 production and T-cell proliferation.
Azopt · Cardiovascular Brinzolamide reduces intraocular pressure by inhibiting carbonic anhydrase II, decreasing aqueous humor secretion.
Beovu · Metabolic Beovu works by binding to vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and reducing vascular permeability and inflammation.
Phase 3 pipeline
Aliskiren 150 · Cardiovascular Aliskiren is a direct renin inhibitor that blocks the first step of the renin-angiotensin-aldosterone system (RAAS) by preventing renin from converting angiotensinogen to angiotensin I.
Aliskiren/HCTZ · Cardiovascular Aliskiren/HCTZ is a fixed-dose combination that lowers blood pressure by blocking the renin-angiotensin system and promoting sodium and water excretion.
Aliskiren+HCTZ+amlodipine - Phase 3 · Cardiovascular This triple-combination drug lowers blood pressure by blocking the renin-angiotensin system (aliskiren), reducing fluid volume (HCTZ), and relaxing blood vessels (amlodipine).
Aliskiren+HCTZ - Phase 2 · Cardiovascular Aliskiren blocks the renin-angiotensin-aldosterone system (RAAS) by inhibiting renin, while HCTZ reduces blood pressure through diuresis and vasodilation.
Amlodipine + HCTZ · Cardiovascular Amlodipine relaxes blood vessels by blocking calcium channels, while HCTZ reduces blood volume by increasing sodium and water excretion through the kidneys, together lowering blood pressure.
amorolfine nail lacquer · Dermatology Amorolfine nail lacquer works by inhibiting the growth of fungi on the nail plate and nail bed.
Basiliximab (Simulect) · Immunology Basiliximab is a chimeric monoclonal antibody that blocks the interleukin-2 (IL-2) receptor on T cells, preventing T cell activation and proliferation.
Benazepril plus hydrochlorothiazide · Cardiovascular Benazepril inhibits angiotensin-converting enzyme (ACE) to reduce blood pressure, while hydrochlorothiazide acts as a thiazide diuretic to promote sodium and water excretion.
Calcium/Vitamin D · Bone Health / Orthopedics Calcium and vitamin D work together to support bone mineralization and maintain serum calcium levels for skeletal health.
Candesartan+HCTZ - Phase 1 · Cardiovascular Candesartan blocks angiotensin II receptors to lower blood pressure, while HCTZ is a thiazide diuretic that reduces fluid volume and sodium reabsorption.
Candesartan plus Hydrochlorothiazide · Cardiovascular Candesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume and sodium reabsorption.
cTIV or eTIV_a · Cardiovascular cTIV is a small molecule that targets the PCSK9 protein to lower LDL cholesterol.
cTIV+PV OR eTIV_a+PV cTIV+PV and eTIV_a+PV are investigational drugs with unknown mechanisms of action.
Depiquick Birch (DPG103) Depiquick Birch (DPG103) is a small molecule that targets the (unknown) mechanism.
Dexmethylphenidate HCl extended-release capsules · Neurology/Psychiatry Dexmethylphenidate HCl is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the presynaptic neuron.
diclofenac diethylamine, DDEA 2.32% gel · Rheumatology Diclofenac diethylamine works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins, leading to a reduction in inflammation and pain.
Everolimus (Certican) · Immunology, Oncology Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.
fluvastatin, ezetimibe · Cardiovascular This combination reduces LDL cholesterol through dual inhibition of cholesterol synthesis and intestinal absorption.
indacaterol maleate/mometasone furoate · Respiratory Indacaterol maleate is a long-acting beta2-adrenergic receptor agonist, while mometasone furoate is an inhaled corticosteroid.
Indacaterol (QAB149) · Respiratory Indacaterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
Interferon β-1a 30 µg · Immunology Interferon β-1a activates interferon-beta receptors on immune cells to enhance antiviral and immunomodulatory responses, reducing inflammation and immune-mediated demyelination.
Lumiracoxib (drug) · Rheumatology / Pain Management Lumiracoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce inflammation and pain.
MenACWY-CRM Vaccine · Immunology / Infectious Disease MenACWY-CRM is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by coupling polysaccharide antigens to a carrier protein.
MenACWY-CRM197 · Immunology / Infectious Disease MenACWY-CRM197 is a meningococcal conjugate vaccine that stimulates immune responses against serogroups A, C, W, and Y by conjugating polysaccharide antigens to a carrier protein (CRM197).
MMF, cyclosporine, steroids · Immunology / Transplantation This triple immunosuppressive regimen suppresses T-cell activation and proliferation through multiple pathways to prevent organ rejection.
Paracetamol (500 mg) tablets · Pain Management Paracetamol inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever.
Placebo to Formoterol · Respiratory Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
Placebo to omalizumab · Immunology Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human immunoglobulin E (IgE) with high affinity.
Placebo to salbutamol · Respiratory Salbutamol is a beta-2 adrenergic agonist that relaxes airway smooth muscle by activating beta-2 receptors, causing bronchodilation.
Placebo to Salmeterol/fluticasone · Respiratory Salmeterol is a long-acting beta2-adrenergic receptor agonist, while fluticasone is a corticosteroid that inhibits inflammatory processes.
Rabies vaccines + Rabies immunoglobulins · Infectious Disease / Immunology Rabies vaccines stimulate immune response against rabies virus, while rabies immunoglobulins provide immediate passive immunity through pre-formed antibodies.
Rivastigmine 10 cm^2 transdermal patch · Neurology Rivastigmine is a cholinesterase inhibitor that works by increasing the concentration of acetylcholine in the brain, which helps to improve cognitive function in patients with Alzheimer's disease.
Rivastigmine 5 cm^2 transdermal patch · Neurology Rivastigmine inhibits acetylcholinesterase and butyrylcholinesterase enzymes, increasing acetylcholine levels in the brain to improve cognitive function.
Salbutamol (200 µg) · Respiratory Salbutamol is a short-acting β2 adrenergic receptor agonist that works by stimulating the β2 receptors in the lungs, causing bronchodilation and relaxation of bronchial smooth muscle.
SBR759A · Oncology SBR759A is a small molecule that targets the PI3K pathway.
Sham ranibizumab · Ophthalmology Sham ranibizumab is a placebo used in clinical trials to compare the efficacy of ranibizumab.
Sham to ranibizumab · Ophthalmology Ranibizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), preventing angiogenesis.